The Consideration of At-Home Administration of Omalizumab
by Anna K Lattos, 2021 PharmD Candidate, Kate Hartkopf PharmD, BCACP, James Langley PharmD, MS
"Part of every pharmacist’s job involves selecting the safest medication regimen to fit each patient’s medical needs and achieve compatibility with individual lifestyles. Over time, developments in monoclonal antibody therapies have provided symptom control benefits for patients living with severe allergic asthma. Omalizumab (Xolair®), a monoclonal antibody medication for IgE-mediated asthma, was approved by the FDA for in-clinic use in 2003. In 2018, the European Commission approved this agent’s use for at-home self-administration; this supported increased access and fewer in-clinic trips for patients. However, in the United States, omalizumab largely remains administered in the clinic only."
Keywords: Omalizumab, Anaphylaxis, Antibodies, Monoclonal, Self Administration, Syringes, Drug Labeling, Pharmacists, COVID-19, Asthma, Epinephrine, Histamine Antagonists, Immunoglobulin E, Risk Factors, Biological Products, Ambulatory Care
Download PDF
2021 January/February Table of Contents
"Part of every pharmacist’s job involves selecting the safest medication regimen to fit each patient’s medical needs and achieve compatibility with individual lifestyles. Over time, developments in monoclonal antibody therapies have provided symptom control benefits for patients living with severe allergic asthma. Omalizumab (Xolair®), a monoclonal antibody medication for IgE-mediated asthma, was approved by the FDA for in-clinic use in 2003. In 2018, the European Commission approved this agent’s use for at-home self-administration; this supported increased access and fewer in-clinic trips for patients. However, in the United States, omalizumab largely remains administered in the clinic only."
Keywords: Omalizumab, Anaphylaxis, Antibodies, Monoclonal, Self Administration, Syringes, Drug Labeling, Pharmacists, COVID-19, Asthma, Epinephrine, Histamine Antagonists, Immunoglobulin E, Risk Factors, Biological Products, Ambulatory Care
Download PDF
2021 January/February Table of Contents